R Eisenberg

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Modulation of autoimmunity by TLR9 in the chronic graft-vs-host model of systemic lupus erythematosus
    Zhongjie Ma
    Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104 6160, USA
    J Immunol 177:7444-50. 2006
  2. pmc T cells, murine chronic graft-versus-host disease and autoimmunity
    Robert A Eisenberg
    Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, 756 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104 6160, USA
    J Autoimmun 39:240-7. 2012
  3. pmc Secondary receptor editing in the generation of autoimmunity
    Robert A Eisenberg
    Division of Rheumatology, University of Pennsylvania, Philadelphia, PA 19104 6160, United States
    Autoimmun Rev 11:787-9. 2012
  4. pmc Why can't we find a new treatment for SLE?
    Robert Eisenberg
    Division of Rheumatology, Department of Medicine, 756 BRBII III, 421 Curie Blvd, University of Pennsylvania, Philadelphia, PA 19104 6160, USA
    J Autoimmun 32:223-30. 2009
  5. ncbi request reprint Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20)
    Robert Eisenberg
    Division of Rheumatology, University of Pennsylvania, Philadelphia 19104, USA
    Endocr Metab Immune Disord Drug Targets 6:345-50. 2006
  6. ncbi request reprint The role of toll-like receptors in systemic lupus erythematosus
    Adeeb H Rahman
    Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Springer Semin Immunopathol 28:131-43. 2006
  7. ncbi request reprint B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus
    Robert Eisenberg
    Medicine and Pathology, University of Pennsylvania, School of Medicine, Philadelphia 19104 6160, USA
    Nat Clin Pract Rheumatol 2:20-7. 2006
  8. pmc Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
    Robert Eisenberg
    Division of Rheumatology, Department of Medicine, University of Pennsylvania, School of Medicine, 756 BRBII III, 421 Curie Boulevard, Philadelphia, PA 19104 6160, USA
    Arthritis Res Ther 8:108. 2006
  9. pmc Update on rituximab
    R Eisenberg
    University of Pennsylvania, PA, USA
    Ann Rheum Dis 64:iv55-7. 2005
  10. ncbi request reprint Do autoantigens define autoimmunity or vice versa?
    Robert Eisenberg
    Division of Rheumatology, University of Pennsylvania School of Medicine, Philadelphia 19104 6160, USA
    Eur J Immunol 35:367-70. 2005

Research Grants

  1. EXPERIMENTAL INDUCTION OF SLE BY ALTERED IA
    Robert Eisenberg; Fiscal Year: 2006
  2. MECHANISMS OF AUTOREACTIVITY IN SLE
    Robert Eisenberg; Fiscal Year: 2007
  3. MECHANISMS OF AUTOREACTIVITY IN SLE
    Robert Eisenberg; Fiscal Year: 2009
  4. EXPERIMENTAL INDUCTION OF SLE BY ALTERED IA
    Robert Eisenberg; Fiscal Year: 2002
  5. MECHANISM OF AUTOREACTIVITY IN SLE
    Robert Eisenberg; Fiscal Year: 2001
  6. EXPERIMENTAL INDUCTION OF SLE BY ALTERED IA
    Robert A Eisenberg; Fiscal Year: 2010

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Modulation of autoimmunity by TLR9 in the chronic graft-vs-host model of systemic lupus erythematosus
    Zhongjie Ma
    Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104 6160, USA
    J Immunol 177:7444-50. 2006
    ..56R and B6.56R.TLR9(-/-) postinduction of cGVH disease. Taken together, these results suggested that TLR9 may worsen some aspects of systemic autoimmunity while alleviating others...
  2. pmc T cells, murine chronic graft-versus-host disease and autoimmunity
    Robert A Eisenberg
    Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, 756 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104 6160, USA
    J Autoimmun 39:240-7. 2012
    ....
  3. pmc Secondary receptor editing in the generation of autoimmunity
    Robert A Eisenberg
    Division of Rheumatology, University of Pennsylvania, Philadelphia, PA 19104 6160, United States
    Autoimmun Rev 11:787-9. 2012
    ..We propose that a pathological autoimmune process can use receptor editing to induce the de novo creation and activation of B cells with autoreactive receptors in the peripheral immune system...
  4. pmc Why can't we find a new treatment for SLE?
    Robert Eisenberg
    Division of Rheumatology, Department of Medicine, 756 BRBII III, 421 Curie Blvd, University of Pennsylvania, Philadelphia, PA 19104 6160, USA
    J Autoimmun 32:223-30. 2009
    ..We need to be persistent and imaginative in identifying these effective agents and proving their efficacy so that they may be widely used in our lupus populations...
  5. ncbi request reprint Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20)
    Robert Eisenberg
    Division of Rheumatology, University of Pennsylvania, Philadelphia 19104, USA
    Endocr Metab Immune Disord Drug Targets 6:345-50. 2006
    ..Two large ongoing randomized controlled trials will determine the efficacy of rituximab in SLE, both renal and extra-renal, and will inform us better about the biology of the B cell in this disease and the effects of B-cell depletion...
  6. ncbi request reprint The role of toll-like receptors in systemic lupus erythematosus
    Adeeb H Rahman
    Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Springer Semin Immunopathol 28:131-43. 2006
    ..Further understanding of the role of TLRs in pathological autoreactivity of the adaptive immune system will likely lead to important insights into the etiopathogenesis of SLE and potential targets for novel therapies...
  7. ncbi request reprint B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus
    Robert Eisenberg
    Medicine and Pathology, University of Pennsylvania, School of Medicine, Philadelphia 19104 6160, USA
    Nat Clin Pract Rheumatol 2:20-7. 2006
    ..We can reasonably expect important advances in the understanding and treatment of RA and SLE in the next 5-10 years, as B-cell targeting methods become more widespread and sophisticated...
  8. pmc Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
    Robert Eisenberg
    Division of Rheumatology, Department of Medicine, University of Pennsylvania, School of Medicine, 756 BRBII III, 421 Curie Boulevard, Philadelphia, PA 19104 6160, USA
    Arthritis Res Ther 8:108. 2006
    ..A randomized controlled trial is currently active to test this possibility...
  9. pmc Update on rituximab
    R Eisenberg
    University of Pennsylvania, PA, USA
    Ann Rheum Dis 64:iv55-7. 2005
  10. ncbi request reprint Do autoantigens define autoimmunity or vice versa?
    Robert Eisenberg
    Division of Rheumatology, University of Pennsylvania School of Medicine, Philadelphia 19104 6160, USA
    Eur J Immunol 35:367-70. 2005
    ..Here I discuss the overall paradigm of autoimmunity, and what kinds of mechanisms might play a role. It is likely that multiple different pathways are critical in various diseases, and even in a single condition...
  11. ncbi request reprint Mechanisms of systemic autoimmunity in murine models of SLE
    R Eisenberg
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
    Immunol Res 17:41-7. 1998
    ..Future investigations will target the biochemistry of the loss of tolerance and the specificity of autoreactive T cells that provide help for autoantibody production...
  12. ncbi request reprint The chronic graft-versus-host model of systemic autoimmunity
    Robert Eisenberg
    Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Curr Dir Autoimmun 6:228-44. 2003
  13. pmc SLE - Rituximab in lupus
    Robert Eisenberg
    Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Arthritis Res Ther 5:157-9. 2003
    ..Controlled trials in SLE will be necessary to determine whether rituximab is useful therapy in this disease, and will teach us more about the roles of B cells in its pathogenesis...
  14. ncbi request reprint Mechanisms of autoimmunity
    Robert Eisenberg
    Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Immunol Res 27:203-18. 2003
    ..We find that the B cell plays a key central role in this process and represents an attractive target for therapeutic intervention...
  15. ncbi request reprint The anti-DNA knock-in model of systemic autoimmunity induced by the chronic graft-vs-host reaction
    Robert Eisenberg
    Department of Medicine, University of Pennsylvania, Philadelphia, USA
    Methods Mol Med 102:273-84. 2004
    ..This permits the examination of the role of somatic immunoglobulin genetics and B-cell tolerance in a model of systemic lupus erythematosus...
  16. ncbi request reprint The therapeutic potential of anti-CD20 "what do B-cells do?"
    Robert Eisenberg
    Division of Rheumatology, University of Pennsylvania, Philadelphia, PA 19104, USA med upenn edu
    Clin Immunol 117:207-13. 2005
    ..The increased use of rituximab, other anti-CD20 agents, and other B-cell targeting therapies holds great promise for substantial clinical benefits, as well as providing special opportunities to understand better disease pathogenesis...
  17. ncbi request reprint Chronic GVH prevents anergy in bone marrow self-reactive B cells: a selective increase in post-endoplasmic reticulum processing and trafficking to the cell surface of autoreactive IgM receptors
    Nili Feuerstein
    Division of Rheumatology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Int Immunol 15:975-85. 2003
    ....
  18. ncbi request reprint Chronic graft-versus-host in Ig knockin transgenic mice abrogates B cell tolerance in anti-double-stranded DNA B cells
    Debora R Sekiguchi
    Department of Medicine, Division of Rheumatology, Wistar Institute, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 168:4142-53. 2002
    ..Thus, our study indicates that alloreactive T cell help can break tolerance in a complex manner, involving several events...
  19. pmc Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice
    Takashi Miwa
    Department of Pharmacology, Center for Experimental Therapeutics, Philadelphia, Pennsylvania, USA
    Am J Pathol 161:1077-86. 2002
    ..These results reveal a protective function of DAF in the development of a systemic autoimmune syndrome and suggest that dysfunction or down-regulation of DAF may contribute to autoimmune disease pathogenesis and manifestation...
  20. pmc B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice
    Yongmei Li
    Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 181:2961-72. 2008
    ..Anti-CD79 mAbs show promise as a potential treatment for systemic lupus erythematosus and as a model for B cell depletion in vivo...
  21. ncbi request reprint The Mer receptor tyrosine kinase is required for the loss of B cell tolerance in the chronic graft-versus-host disease model of systemic lupus erythematosus
    Wen Hai Shao
    Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 180:7728-35. 2008
    ..These findings indicate that Mer serves an important role in the activation of self-reactive B cells in systemic autoimmunity...
  22. pmc Accelerated atherosclerosis in ApoE deficient lupus mouse models
    Zhongjie Ma
    Divisions of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Immunol 127:168-75. 2008
    ..These observations define a connection between induction of lupus-like symptoms and development of severe atherosclerosis in ApoE deficient lupus mouse models...
  23. doi request reprint A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery
    Jennifer A Sutter
    Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, 405B Stellar Chance Labs, 422 Curie Boulevard, Philadelphia, PA 19104, USA
    Clin Immunol 126:282-90. 2008
    ..Further refinement of these potential biomarkers may lead to a better understanding of the role of B cells in disease pathogenesis and a more rational use of B cell depletion therapies...
  24. ncbi request reprint TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus
    Zeguo Zhao
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Immunol 179:7949-58. 2007
    ..Thus, TWEAK blockade may be a novel therapeutic approach to reduce renal damage in SLE...
  25. ncbi request reprint Mature B cells preferentially lose tolerance in the chronic graft-versus-host disease model of systemic lupus erythematosus
    Arpita Choudhury
    Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 179:5564-70. 2007
    ..This observation underscores the critical role of marginal zone B cells in activation and production of autoantibodies...
  26. ncbi request reprint Chronic graft-versus-host reaction is associated with a decrease in Ig light chain receptor editing in bone marrow self-reactive B cells
    Nili Feuerstein
    Division of Rheumatology, The Children s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, 19104, USA
    Eur J Immunol 34:1361-70. 2004
    ..Thus, the autoimmunity induced by chronic GVH may ultimately result from the failure of B cell tolerance at multiple checkpoints...
  27. ncbi request reprint The role of host CD4 T cells in the pathogenesis of the chronic graft-versus-host model of systemic lupus erythematosus
    Arpita Choudhury
    Department of Medicine, Division of Rheumatology, University of Pennsylvania, and Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    J Immunol 174:7600-9. 2005
    ..These studies clearly indicate that B cells need to coexist with CD4 T cells early in their development to develop full susceptibility to alloactivation signals...
  28. pmc Secondary heavy chain rearrangement: a mechanism for generating anti-double-stranded DNA B cells
    Debora R Sekiguchi
    Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Exp Med 197:27-39. 2003
    ..Genetic analysis associated this response with the generation of anti-dsDNA B cells through secondary rearrangements that replaced the site-directed transgene (sd-tg) with endogenous VH genes...
  29. pmc Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms
    Takashi Miwa
    Institute for Translational Medicine and Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, 1254 BRBII III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Am J Pathol 170:1258-66. 2007
    ..Together, these results reveal multiple mechanisms of action for DAF in ameliorating systemic autoimmunity...

Research Grants24

  1. EXPERIMENTAL INDUCTION OF SLE BY ALTERED IA
    Robert Eisenberg; Fiscal Year: 2006
    ..Since this process of tolerance loss is central to the pathogenesis of SLE, the results will help clarify some of the fundamental underlying mechanisms of this disease. ..
  2. MECHANISMS OF AUTOREACTIVITY IN SLE
    Robert Eisenberg; Fiscal Year: 2007
    ..Such insights should be readily translatable to human autoimmune diseases. ..
  3. MECHANISMS OF AUTOREACTIVITY IN SLE
    Robert Eisenberg; Fiscal Year: 2009
    ..Such insights should be readily translatable to human autoimmune diseases. ..
  4. EXPERIMENTAL INDUCTION OF SLE BY ALTERED IA
    Robert Eisenberg; Fiscal Year: 2002
    ..Such understanding will, eventually, lead to more rational therapy for this disease and other autoimmune diseases. ..
  5. MECHANISM OF AUTOREACTIVITY IN SLE
    Robert Eisenberg; Fiscal Year: 2001
    ..Is the pace of MRL/lpr disease dictated by events that occur after the early lymphocyte stage of ontogeny? 4. Does the genotype of the B cell control the lymphoproliferation of T cells? ..
  6. EXPERIMENTAL INDUCTION OF SLE BY ALTERED IA
    Robert A Eisenberg; Fiscal Year: 2010
    ..The knowledge gained will improve of our understanding of the pathogenesis of systemic lupus erythematosus and how we can target the B lymphocytes in treatment. ..